Quick Answer
Altimmune, Inc. reported Cash And Cash Equivalents At Carrying Value of $43.76 million for the year ending 2025.
- Altimmune, Inc. showed an increase of +18.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Altimmune, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,536.8%.
- Historical annual values: Fiscal year 2025: $43.76 million | Fiscal year 2024: $36.93 million | Fiscal year 2023: $135.12 million | Fiscal year 2022: $111.10 million | Fiscal year 2021: $190.30 million | Fiscal year 2020: $115.92 million | Fiscal year 2019: $8.96 million | Fiscal year 2018: $33.72 million | Fiscal year 2017: $8.77 million | Fiscal year 2016: $2.88 million | Fiscal year 2015: $15.57 million | Fiscal year 2014: $18.64 million | Fiscal year 2013: $10.48 million | Fiscal year 2012: $12.70 million | Fiscal year 2011: $11.24 million | Fiscal year 2010: $11.79 million | Fiscal year 2009: $2.67 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: